Modafinil for the treatment of pain-associated fatigue: Review and case report

Journal of Pain and Palliative Care Pharmacotherapy

Volumn 18, Issue 2, 2004, Pages 39-47

  Fishbain, David A ^a,b   Cutler, R B ^a,b   Lewis, J ^a,b   Cole, B ^b   Rosomoff, H L ^a,c   Steele Rosomoff, R ^a,c  

^a Department of Psychiatry ^*

^b Rosomoff Compreh Pain/Rehab Ctr   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Case report; Fatigue; Modafinil; Pain; Review

Indexed keywords

ANTIDEPRESSANT AGENT; MODAFINIL;

ADULT; ANXIETY DISORDER; CASE REPORT; CHRONIC PAIN; CLINICAL FEATURE; DEPRESSION; DISEASE ASSOCIATION; DISEASE COURSE; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG MECHANISM; FATIGUE; FEMALE; HUMAN; LOW BACK PAIN; MASSAGE; NECK PAIN; OCCUPATIONAL THERAPY; PHYSIOTHERAPY; PSYCHOTHERAPY; REVIEW; WAKEFULNESS;

EID: 3543147094     PISSN: 15360288     EISSN: None     Source Type: Journal    
DOI: 10.1080/J354v18n02_04     Document Type: Review

References (43)

1. Makela E, Miller K, Cutlip W. Three case reports of modafinil use in treating sedation induced by antipsychotic medications. J Clin Psychiatry 2003;64(4):485-86.
2. Portenoy R, Miaskowski C. Assessment and management of fatigue. In: Berger, R.K. Portenoy & D. Weissman (Eds.) Principles & Practice of Supportive Oncology. Philadelphia: Lippincott-Rowe Press, 1998.
3. Mengshoel A, Saugen E, Forre O. Vollestad N. Muscle fatigue in early fibromyalgia. J Rheum 1995;22(1):143-50.
4. Wolfe F, Hawley DJ, Wilson K. The prevalence and meaning of fatigue in rheumatic disease. J Rheumatol 1996;23:1407-17.
5. Godenberg D, Simms R, Geiger A, Komaroff A. High frequency of fibromyalgia in patients with chronic fatigue seen in a primary care practice. Arthritis Rheum 1990;33:381-7.
6. Bansevicius D, Westgaard R, Sjaastad O. Tension-type headache; pain, fatigue, tension, and responses to mental activation. Headache 1999;39(6):417-25.
7. Pawlikowska T, Chalder T, Hirsch S. Population based study of fatigue and psychological distress. BMJ 1994;308:763-77.
8. Chen M. The epidemiology of self-perceived fatigue among adults. Preventive Medicine 1986;15:74-81.
9. Tack B. Fatigue in rheumatoid arthritis: conditions, strategies, and consequences. Arthritis Care Res 1990;3(2):65-70.
10. Belza B. Comparison of self-reported fatigue in rheumatoid arthritis and controls. J Rheum 1995;22(4):639-43.
11. Tack B. Dimensions and correlates of fatigue in older adults with rheumatoid arthritis. Dissertation Abstracts International 1991;51:6621.
12. Feuerstein M, Carter R, Papciak A. A prospective analysis of stress and fatigue in recurrent low back pain. Pain 1987;31(3):333-44.
13. Fishbain DA, Cutler RB, Cole B, Lewis J, Smets E, Rosomoff HL, Steele-Rosomoff R. Are patients with chronic low back pain and/or neck pain fatigued? Accepted for publication, Pain Medicine.
14. Fishbain DA, Cole B, Cutler RB, Lewis J, Rosomoff HL, Steele-Rosomoff R. Is pain fatiguing? A structured evidence-based review. Pain Medicine 2003;4(1):51-62.
15. Fishbain DA, Cutler RB, Lewis J, Cole B, Rosomoff HL, Steele-Rosomoff HL. Improvement in pain associated fatigue with multidisciplinary treatment: a treatment outcome study. Accepted for publication, Pain Medicine.
16. Beusterien KM, Rogers AE, Walsleben JA, et al. Health-related qualify of life effects of modafinil for treatment of narcolepsy. Sleep 1999;22:757-65.
17. US Modafinil in Narcolepsy Multicenter Study Group. Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. Annals of Neurology 1998;43:88-96.
18. Lin JS, Roussel B, Akaoka H, et al. Role of catecholamines in the modafinil and amphetamine induced wakefulness, a comparative pharmacological study in the cat. Brain Res 1992;591:319-26.
19. Ferraro L, Antonelli T, O'Connor WT. Modafinil: An anti-narcoleptic drug with a different neurochemical profile to d-amphetamine and dopamine uptake blockers. Biol Psychiatry 1997;42:1181-3.
20. Lyons TJ, French J. Modafinil: The unique properties of a new stimulant. Aviation Space & Environmental Med 1991;62(5):432-5.
21. Duteil J, deSereville J, Boer C, Rambert FA. Lack of dopaminergic involvement in modafinil, but not amphetamine and methylphenidate, activity in anaesthetized mice and rats: in vivo voltammetry studies. Eur J Pharmacol 1990;183:1406-7.
22. Engber TM, Koury EJ, Dennis SA, et al. Differential patterns of regional c-Fos induction in the rat brain by amphetamine and the novel wakefulness-promoting agent modafinil. Neuroscience Letters 1998;241:95-8.
23. Lin JS, Hou Y, Jouvet M. Potential brain neuronal targets for amphetamine-, methylphenidate-, and modafinil-induced wakefulness, evidenced by c-fos immunocytochemistry in the cat. Proc Natl Acad Sci 1996;93:14127-33.
24. Scammel TE, Estabrooke IV, McCarthy MT, et al. Hypothalamic arousal regions are activated during modafinil-induced wakefulness. J Neurosci 2000;20:8620-8.
25. Stahl SM. Awakening to the psychopharmacology of sleep and arousal: Novel neurotransmitters and wake-promoting drugs. J Clin Psychiatry 2002;63:467-8.
26. Jasinski DR. An evaluation of the abuse potential of modafinil using methylphenidate as a reference. J Psychopharmacol 200;14(1):53-60.
27. O'Malley MB. Long-term safety and efficacy of modafinil for daytime sleepiness. Presented at: 2002 Annual Meeting of the American Psychiatric Association. May 18-23,2002: Philadelphia.
28. Gold LH, Belster RL. Evaluation of the cocaine-like discriminative stimulus effects and reinforcing effects of modafinil. Psychopharmacol 1996;126(4):286-92.
29. Warot D, Coruble E, Payan C, et. al. Subjective effects of modafinil, a new central adrenergic stimulant in healthy volunteers: A comparison with amphetamine, caffeine and placebo. Eur Psychiatry 1993;8:201-8.
30. Duteil J, Rambert FA, Pessonnier J, et al. Central alpha 1-adrenergic stimulation in relation to the behaviour stimulating effects of modafinil: Studies with experimental animals. Eur J Pharmacol 1990;180:49-58.
31. Wong YN, Simcoe D, Hartman LN, et al. A double-blind placebo-controlled, ascending-dose evaluation of the pharmacokinetics and tolerability of modafinil tablets in healthy male volunteers. J Clin Pharmacol 1999;39:30-40.
32. Arnulf I, Homeyer P, Garma L, et al. Modafinil in obstructive sleep apnea-hypopnea syndrome: A pilot study in 6 patients. Respiration. 1997;64:159-61.
33. Elovic E. Use of Provigil for underarousal following TBI. J Head Trauma Rehab 2000;15(4):1068-71.
34. Yu BP, Maguire GA. Can a wakefulness-promoting agent augment schizophrenia treatment? 2002;1(7):52-7.
35. Sherman C. Modafinil may reduce residual fatigue, sleepiness. Clin Psychiatry News 2002;2:July:16.
36. MacDonald JR, Hill JD, Tarnopolsky MA. Modafinil reduces excessive somnolence and enhances mood in patients with myotonic dystrophy. Neurology 2002;59(12):1876-80.
37. Zifko UA, Rupp M, Schwarz S, Zipko HT, Maida EM. Modafinil in treatment of fatigue in multiple sclerosis. Results of an open-label study. J Neurol 2002;249(8):983-7.
38. Rammohan KW, Rosenberg JH, Lynn DJ, Blumenfeld AM, Pollak CP, Nagaraja HN. Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: A two centre phase 2 study. J Neurol Neurosurg Psychiatry 2002;72(2): 179-83.
39. Disdier P, Genton P, Milandre C, Bernard PM, Millet Y. Fibrositis syndrome and narcolepsy. J Rheumatol 1993;20:888-9.
40. Schaller JL, Behar D. Modafinil in fibromyalgia treatment. J Neuropsychiatry Clin Neurosci 2001;13(4):530-1.
41. Pachas WN. Modafinil may be a suitable treatment for the fatigue of fibromyalgia. Presented at the 5th World Congress on Myofascial Pain and Fibromyalgia. Portland, Oregon, September 2001.
42. Coffman JA, Dilsaver SC, Smeltzer DJ, O'Donnell V, Olson SC. Sample bias and over inference: Two sources of error in interpreting case report data. (Letter). J Clin Psych 1989;50(3):105.
43. Menza MA, Kaufman KR, Castellanos A. Modafinil augmentation of antidepressant treatment in depression. J Clin Psychiatry 2000;61(5):378-81.